Studies suggest that CDP-choline supplements increase dopamine receptor densities, and suggest that CDP-choline supplementation helps prevent memory impairment resulting from poor environmental conditions. Preliminary research has found that citicoline supplements help improve focus and mental energy and may possibly be useful in the treatment of attention deficit disorder. Citicoline has also been shown to elevate ACTH independently from CRH levels and to amplify the release of other HPA axis hormones such as LH, FSH, GH and TSH in response to hypothalamic releasing factors. These effects on HPA hormone levels may be beneficial for some individuals but may have undesirable effects in those with medical conditions featuring ACTH or cortisol hypersecretion including, but not limited to, PCOS, type II diabetes and major depressive disorder.
In the hippocampi of rats with induced Alzheimer’s Disease, citicoline counteracts neuronal degeneration and reduces the number of apoptotic cells present. Citicoline supplementation also improves memory retention.
Citicoline is approved for treatment in cases of head trauma, stroke, and neurodegenerative disease in Japan and Europe. Citicoline improves the clinical outcome following an ischemic stroke, as evinced by the reduction in size of lesions caused by ischemic strokes after supplementation. It has been claimed that citicoline reduces rates of death and disability following an ischemic stroke. However, the largest trial to date, a randomised, placebo-controlled, sequential trial in patients with moderate-to-severe acute ischaemic stroke in Europe, enrolling 2298 patients, found no benefit of administering citicoline on survival or recovery from stroke.
Citicoline improves visual function in patients with glaucoma, amblyopia, and non-arteritic ischaemic optic neuropathy.
Cocaine dependence is associated with depleted dopamine levels in the central nervous system. In cocaine-dependent individuals citicoline increases brain dopamine levels and reduces cravings. In the general population citicoline increases brain responses to food stimuli, specifically in the amygdala, insula, and lateral orbitofrontal cortex, which correlate with decreased appetite.
Mechanism of action
Enzymes involved in reactions are identified by numbers. See file description.
Citicolene is used in conjunction with cannabis oil to mitigate the anxious feelings often caused by high doses of THC. It is further believed that citicoline stimulates CB1 receptors found in the brain. Dr. Robert Melamede will be publishing articles to this effect in the near future.
Citicoline lowers increased glutamate concentrations and raises decreased ATP concentrations induced by ischemia. Citicoline also increases glutamate uptake by increasing expression of EAAT2, a glutamate transporter, in vitro in rat astrocytes. It is suggested that the neuroprotective effects of citicoline after a stroke are due in part to citicoline’s ability to decrease levels of glutamate in the brain.
Citicoline is water-soluble, with more than 90% oral bioavailability. Plasma levels peak one hour after oral ingestion, and a majority of the citicoline is excreted as CO2 in respiration, and again 24 hours after ingestion, where the remaining citicoline is excreted through urine.
The most effective oral dosages appear to be between 500 and 2,000 mg.
Citicoline has a very low toxicity profile in animals and humans. Clinically, doses of 2000 mg per day have been observed and approved. Minor transient adverse effects are rare and most commonly include stomach pain and diarrhea.
phosphatidylcholine is a major phospholipid in eukaryotic cell membranes. Close regulation of its biosynthesis, degradation, and distribution is essential to proper cell function. phosphatidylcholine is synthesized in vivo by two pathways
^Silveri MM, Dikan J, Ross AJ, et al. (November 2008). "Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy". NMR in Biomedicine21 (10): 1066–75. doi:10.1002/nbm.1281. PMID18816480.Cite uses deprecated parameters (help)
^Cavun S, Savci V (October 2004). "CDP-choline increases plasma ACTH and potentiates the stimulated release of GH, TSH and LH: the cholinergic involvement". Fundamental & Clinical Pharmacology18 (5): 513–23. doi:10.1111/j.1472-8206.2004.00272.x. PMID15482372.Cite uses deprecated parameters (help)
^Florio P, Zatelli MC, Reis FM, degli Uberti EC, Petraglia F (2007). "Corticotropin releasing hormone: a diagnostic marker for behavioral and reproductive disorders?". Frontiers in Bioscience12: 551–60. doi:10.2741/2081. PMID17127316.
^ abAlvarez, XA; Sampedro, C; Lozano, R; Cacabelos, R (October 1999). "Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats.". Methods and findings in experimental and clinical pharmacology21 (8): 535–40. PMID10599052.Cite uses deprecated parameters (help)
^Carlezon, WA; Pliakas, AM; Parow, AM; Detke, MJ; Cohen, BM; Renshaw, PF (Jun 1, 2002). "Antidepressant-like effects of cytidine in the forced swim test in rats.". Biological Psychiatry51 (11): 882–9. PMID12022961.Cite uses deprecated parameters (help)
^Warach, S; Pettigrew, LC; Dashe, JF; Pullicino, P; Lefkowitz, DM; Sabounjian, L; Harnett, K; Schwiderski, U; Gammans, R (November 2000). "Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators.". Annals of neurology48 (5): 713–22. PMID11079534.Cite uses deprecated parameters (help)
^Saver, JL (2008 Fall). "Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair.". Reviews in neurological diseases5 (4): 167–77. PMID19122569.Check date values in: |date= (help)
^Parisi, V; Coppola, G; Centofanti, M; Oddone, F; Angrisani, AM; Ziccardi, L; Ricci, B; Quaranta, L; Manni, G (2008). "Evidence of the neuroprotective role of citicoline in glaucoma patients.". Progress in brain research173: 541–54. doi:10.1016/S0079-6123(08)01137-0. PMID18929133.Cite uses deprecated parameters (help)
^Parisi, V.; Coppola, G.; Ziccardi, L.; Gallinaro, G.; Falsini, B. (1 May 2008). "Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy". European Journal of Neurology15 (5): 465–474. doi:10.1111/j.1468-1331.2008.02099.x.Cite uses deprecated parameters (help)
^Renshaw, PF; Daniels, S; Lundahl, LH; Rogers, V; Lukas, SE (February 1999). "Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report.". Psychopharmacology142 (2): 132–8. PMID10102764.Cite uses deprecated parameters (help)
^López-Coviella, I; Agut, J; Savci, V; Ortiz, JA; Wurtman, RJ (August 1995). "Evidence that 5'-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels.". Journal of Neurochemistry65 (2): 889–94. PMID7616250.Cite uses deprecated parameters (help)
^ abcConant, R; Schauss, AG (March 2004). "Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature.". Alternative medicine review : a journal of clinical therapeutic9 (1): 17–31. PMID15005642.Cite uses deprecated parameters (help)
^Babb, SM; Wald, LL; Cohen, BM; Villafuerte, RA; Gruber, SA; Yurgelun-Todd, DA; Renshaw, PF (May 2002). "Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study.". Psychopharmacology161 (3): 248–54. doi:10.1007/s00213-002-1045-y. PMID12021827.Cite uses deprecated parameters (help)
^Rao, AM; Hatcher, JF; Dempsey, RJ (Dec 1, 1999). "CDP-choline: neuroprotection in transient forebrain ischemia of gerbils.". Journal of neuroscience research58 (5): 697–705. PMID10561698.Cite uses deprecated parameters (help)
^ abD'Orlando, KJ; Sandage BW, Jr (August 1995). "Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury.". Neurological research17 (4): 281–4. PMID7477743.Cite uses deprecated parameters (help)
^Fernández-Murray, JP; McMaster, CR (Nov 18, 2005). "Glycerophosphocholine catabolism as a new route for choline formation for phosphatidylcholine synthesis by the Kennedy pathway.". The Journal of Biological Chemistry280 (46): 38290–6. doi:10.1074/jbc.M507700200. PMID16172116.Cite uses deprecated parameters (help)